LONDON, UK / ACCESSWIRE / December 27, 2017 / Active-Investors.com has just released a free research report on Zimmer Biomet Holdings, Inc. (NYSE: ZBH). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZBH as the Company's latest news hit the wire. On December 22, 2017, the Company declared that it has published positive results from PROGRESS II trial, demonstrating the safety and efficacy of the nSTRIDE® Autologous Protein Solution (APS) Kit, prepared by using Zimmer Biomet's nSTRIDE APS Kit, for the treatment of knee osteoarthritis (OA). The results were published in The American Journal of Sports Medicine1, and showed significant improvement in the percentage change from baseline in pain scores measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) as well as comparable safety to saline. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zimmer Biomet most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ZBH

Positive Results of PROGRESS II Trial Accelerate Commercial Expansion in Europe and Asia/Pacific

David Nolan, Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions, stated that the positive results of the PROGRESS II trial not only reinforce the safety and clinical value of the autologous anti-inflammatory protein solution prepared with the nSTRIDE APS Kit, but also lay the groundwork to advance the Company's regulatory efforts in the United States and accelerate its commercial adoption and expansion in Europe and Asia/Pacific.

The nSTRIDE APS Kit is currently marketed in Europe, via CE Mark, and marketed as the APS Kit in Japan, but not yet available in the United States. Results from the PROGRESS II study formed the basis for two additional confirmatory trials, the PROGRESS IV trial which received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) in July 2016, and the PROGRESS V trial, which is underway in Europe to support global reimbursement efforts.

PROGRESS II Trial

The PROGRESS II trial, a prospective, randomized, double-blind, saline-controlled pilot study, enrolled 46 patients with unilateral, mild-to-moderate, symptomatic OA pain from trial sites across Europe. Patients were randomized to receive a single injection of APS prepared by the nSTRIDE APS Kit. Patients treated with APS demonstrated 65% change in WOMAC pain score from baseline to 12 months compared to a 41% change in the saline group was observed, 49% improvement in VAS pain scores compared to 13% improvement in the saline group. No serious adverse events were reported.

FDA's Recently Approved Drug for Treatment of OA

On October 06, 2017, the US FDA approved Flexion Therapeutics' Zilretta? (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for OA pain. Zilretta is a non-opioid medicine that employs Flexion's proprietary microsphere technology to provide proven pain relief over 12 weeks.

About nSTRIDE APS Kit

The device concentrates anti-inflammatory cytokines and growth factors from a sample of the patient's blood. It is then injected into the knee joint. The output of the nSTRIDE APS Kit contains white blood cells and their corresponding anti-inflammatory cytokines in concentrations much higher than that of whole blood, in addition to anabolic cytokines. These anti-inflammatory cytokines target and inhibit the pro-inflammatory and catabolic cytokines Interleukin-1 (IL-1) and Tumor Necrosis Factor Alpha (TNF?).

What is Knee Osteoarthritis?

OA, also known as wear-and-tear arthritis, is a condition in which the natural cushioning between joints cartilage wears away, and the most common type of arthritis. When this happens, the bones of the joints rub more closely against one another with less of the shock-absorbing benefits of cartilage. The rubbing results in pain, swelling, stiffness, decreased ability to move and, sometimes, the formation of bone spurs.

About Zimmer Biomet Holdings, Inc.

Founded in 1927, Zimmer Biomet Holdings, Inc. (formerly known as Zimmer Holdings, Inc.) is a leading innovator in musculoskeletal healthcare, offering a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. Headquartered in Warsaw, Indiana, Zimmer Biomet serves healthcare professionals globally.

Stock Performance Snapshot

December 26, 2017 - At Tuesday's closing bell, Zimmer Biomet's stock was marginally down 0.13%, ending the trading session at $119.96.

Volume traded for the day: 372.89 thousand shares.

Stock performance in the last month - up 6.09%; previous three-month period - up 4.54%; past twelve-month period - up 17.24%; and year-to-date - up 16.24%

After yesterday's close, Zimmer Biomet's market cap was at $24.25 billion.

Price to Earnings (P/E) ratio was at 37.42.

The stock has a dividend yield of 0.80%.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors